Social Media Wiki

Pharma Should Forget About Social Media Monitoring

Dose of Digital Mini White Paper

That Sham Wow Guy

<Play along and use your best infomercial voice to read this first paragraph.>

Do you find yourself frustrated that you can’t take action when you see something bad said about your product on Facebook? Do you find yourself secretly logging in at home to see what bloggers are saying about you? Do you fret that bad things are being said about your brand on WebMD, but you can’t go and check? Do you have a passing interest in Twitter, but don’t want to spend hours figuring out how it works? Well, then social media monitoring is NOT for you!

<Okay, you can stop the voice now.>

That’s right, for most pharma and healthcare marketers, you should just forget about social media monitoring. I know, I know. Didn’t I tell everyone that one of the principles of pharma and healthcare social media participation was “Monitor and Get Involved.” I did. I’ve had this in  presentations for a while, but now I’m wondering why. Why is it such a big deal to monitor social media?

I’m certainly not the first to suggest that monitoring is a good first step into social media. It’s included as the first step in so many lists, that I can’t include them all here. I know you’ve all heard it before in many different places, so it’s almost a rule. The first step to getting involved in social media is monitoring. Right?

Are you sure?

Of course, there are a lot of benefits to monitoring and the rationale for doing this as a first step appears pretty sound. While you’re trying to figure out how best to leverage a certain social media channel, say, Twitter, why not start just by seeing what others are saying? You can use this information to get a sense for how your brand is perceived in the market and what people are saying. Is it all good? Are they consistent? Are they actually saying anything or do they not care? Is there one thing that you didn’t know? Does it even really pertain to your brand or is incredibly general (e.g., just took my Lipitor)? You might find some informative information and you’ll get a little sense for what people say about you when they aren’t in a focus group saying what they think you want to hear. Great. At the same time, while your monitoring, you can also learn a bit of the etiquette of the channel. Using Twitter as an example, you’ll see how the @ works and what the # is and how to use it (and how not to).

There you go…two reasons to monitor just like that. So, why would I tell you to forget about monitoring? It’s simple really.

Since we’re talking about pharma and healthcare here, I thought I’d use this healthcare analogy. Doctors and other healthcare professionals have a pretty simple rule when it comes to ordering tests: do the test only if the results are capable of telling me to change my treatment decision. That is, if I’m thinking I should do surgery and I have one more test I could do, would the results of the test, no matter what they were, convince me not to do surgery? If the answer to that question is “no,” then why do the test? You already have done tests and some sort of examination that said surgery was the right choice, so why do another test if it’s not going to change your recommendation?

Social media monitoring in pharma is just like this last test. Is monitoring, namely what you find out, going to change what you do? Is it going to change your marketing approach? Is it going to spring you into action? Are you going to actively respond? The answer is probably “no.” So why subject your patient, I mean you, to an unnecessary (and potentially invasive) test?

“But wait,” you say, “we are going to do something different. This will give us some insights into our products and  it’ll give us a great marketing idea.” Really? Here’s how this could go wrong: you could actually do this this. Change your marketing plan based on something you see via your monitoring efforts. Let’s say for a moment that you notice time and time again that people are something as clear cut as, “I know they say that Drug X works really well, but I was shocked how inexpensive it was.” (I know, a stretch, but stay with me.) You notice this a few times in a few places. At what point do you see it enough to change your marketing message? At what point do you focus on the cost a bit more in your communications? 10 tweets? 100? 1,000? Maybe 50 Facebook updates? 15 blog posts? At what point do you know it’s something real and not some sort of anomaly?

You can’t. At least, you can’t by yourself. In order to actually use monitoring to inform you about marketing decisions such as brand messaging, you need something much more robust than you doing a Twitter search and making a few notes. It’s a big commitment. Still think you can do it alone? Great. Here’s what you need to collect:

  • number of brand mentions and the content of each (make sure to include links from the mentions)
  • the tone and sentiment of EVERY mention (positive, negative, or neutral)
  • context of the mention (you’ve got to filter out everything irrelevant like spam mentions)

Okay, that’s a good start. There are a few more, but let’s go with that. There’s still more to do. Do you like Excel? You’d better. Love statistics? You’ll learn to. Because now you’ve got to take all the information you gathered and start to look for patterns, trends over time, and where changes occurred. You then need to correlate this with market events and your brand communications. I’d use about a year’s worth of data to get started. Go ahead…I’ll wait.

If you chose to actually do this by yourself and now are coming back to read the rest of this post, it’s probably October 2010. Most of what you figured out is probably outdated. Sorry about that.

My point with all of this is to say that without a formal plan of what you’ll do with your monitoring efforts, it might just be a waste of time. There are a lot of companies out there that would be happy to help you with this. Some of these tools are free and some are very expensive. This is definitely a category where you get what you pay for. Most expensive isn’t necessarily best, but expect to pay big to do a robust analysis that is going to give you solutions and not just more mountains of data. You do have a budget for this, right?

One other reason why monitoring might not be for you…you’re not allowed. Your company may restrict the sites you can access at work and chances are these include some (if not all) social media sites. Why? I’m not sure, but two possible  reasons. First, they think that you’re going to waste your time all day playing with Facebook. They do this despite the fact that at least one study has shown an INCREASE in productivity when these sites aren’t blocked. Second, they don’t want to know. If you go out and look what other people are saying about your brand and uncover someone talking about an adverse event, you’ve got to report it to the FDA. If it’s not reported directly to you, then you’re not responsible for reporting it. That is, if someone posts an adverse event on WebMD, then you don’t have to regularly go through WebMD and report all of these. But if you see it, then that counts the same as if it were reported directly to you. I’m not implying that pharma companies are trying to sweep this information under the rug, but there’s a reason why more pharma companies aren’t using social media. Dealing with all these reports could be a major pain. For those adverse event mentions that don’t have all the criteria required for submission, you’ve got to try to find the other criteria. When you do have all the criteria, you’ve got to catalog, eliminate duplicates, prepare a submission, send it to the FDA, and prepare to answer their follow up questions (if they have any). There are processes already in place at companies to do this, but they’re not capable of handling this on a giant scale.

If your company doesn’t want you monitoring, then that’s a good indication that you shouldn’t. I’ve heard that a lot of pharma marketers simply log onto these sites at home where they have access to take a look. Of course, as an agent of the company, whether at home or not, they still have to report what they find. How much they’ll actually find is a matter of debate, but you’d should be prepared. Most adverse event mentions won’t have all four criteria (actually only 1 in 500 will), but each company has a different policy about whether they try to find the other two by attempting to contact the person who reported it or if they just gather it all and try to submit it as is. Either way, before you jump in, make sure you’re ready to handle what’s out there.

Just so you don’t feel alone, few companies actually permit social media monitoring according to a poll Len Starnes put together. The poll found that 29% of respondents said there was no internal policy. 7% said monitoring was strictly prohibited no matter what. The rest were shades of “yes” including “yes, but.” See the entire poll here.

The final reason why you shouldn’t monitor is because you might do more harm than good. You start a company Twitter account with the idea that you’re just going to see what people are saying, but you figured you may as well have an account too. Great. Now what happens when someone contacts you? They send you a DM or an @ and want an answer. Do you answer them? Are you allowed? What if you’re on WebMD looking through the forums and see a post that says something like: “If someone doesn’t tell me a way to get this drug for less, I can’t refill my prescription next month.” Now, you know from looking at the rest of the post that this person would be an ideal candidate for your assistance program and would probably get their drug for free. Do you say something? What if you do it anonymously?

If these are hard questions to answer, then you shouldn’t even be looking. When people discover that you’re online and available (and they will), they’re going to come to you looking for answers. If you ignore them, then you’ll do more harm than good, as people will only be annoyed with you.

Okay, so have I talked you out of monitoring yet? No? You’re still going forward. <Gulp> In that case, let’s set a few ground rules. You’ll have to agree to each of these in order to be allowed to monitor social media (on the honor system):

  • I will develop a plan of what to do with what I find BEFORE I monitor.
  • I won’t make any marketing decisions based on my own “analysis.” I’ll find an outside partner who will do this for me.
  • I’ll figure out if my company has a social media participation policy. If so, I’ll follow it, so I don’t get fired and blame this blog. If not, I’ll see if we have any rules about adverse events I may uncover and I’ll help fight to get some formal rules set up.
  • When I do participate, I’ll actually participate. I won’t just be a “lurker” on the sidelines, ignoring everyone that wants to talk with me.

Agree? Okay, good. Now go forth and monitor. Try the two below to get started…and be careful. There’s a lot you’ll find out there that will surprise, bewilder, delight, confuse, frustrate, and annoy you. That’s normal. No need for me to order another test. You’re just monitoring social media.

Pharma and Healthcare Social Media Wiki Updates (and Badges!)

The updates continue on the Pharma and Healthcare Social Media Wiki. I’ve added about 20 more listings today, which brings the total pretty close to 400 examples of pharma and healthcare social media programs. Thanks to everyone who continues to send recommendations for sites and programs to include in the wiki.

Many of you have asked what you can do to support the wiki, as you’ve found it so useful. Well, there are a few things you can do since you asked:

  • First and foremost, without your contributions, the wiki wouldn’t be what it is today and it would quickly become outdated. You can submit your recommendations for inclusion (including your own site) using this form.
  • Share with your network. Here are some shortcuts:  Send a tweet, update your LinkedIn or Facebook status, and/or whatever your preferred means of sharing is. You can just copy and paste this: “Pharma and Healthcare Social Media Wiki. http://su.pr/20M8CB. (via @jonmrich)”
  • Write about it. Feel free to blog about the wiki and use some of the examples in case studies or presentations you’re developing.
  • Get a badge. That’s right, if you’re listed on the wiki, you can now add a badge to your site to show that you’ve made it to the list. We’ve created a couple of options to choose from.

<strong>Note:</strong> some of you who have tried to use the code told me that it wasn’t working for you. I’ve fixed the problem, so these should work fine now.

Option 1

Dose of Digital Pharma and Social Media Wiki Badge v1

Copy and paste the code below onto your site:

<form><a href="http://www.doseofdigital.com/healthcare-pharma-social-media-wiki/" target="_blank"><img src="http://www.doseofdigital.com/wp-content/uploads/2009/08/doseofdigitalwikibadge1.jpg"/></a></form>

Option 2

Dose of Digital Pharma and Social Media Wiki Badge v2

Copy and paste the code below onto your site:

<form><a href="http://www.doseofdigital.com/healthcare-pharma-social-media-wiki/" target="_blank"><img src="http://www.doseofdigital.com/wp-content/uploads/2009/08/doseofdigitalwikibadge2.jpg"/></a></form>

Again, thank you all for your contributions. If you have any suggestions on how to improve the wiki, please let me know. We’ll be undertaking a big design and organization project some time soon, so feel free to weigh in now.

6 Steps to Getting Your Healthcare Social Media Idea Approved

Dose of Digital Mini White Paper

Ready for this revelation? The healthcare industry, particularly pharma, is heavily regulated. I know, a shock to all of you. You also probably have heard that every company in this industry has a team of lawyers and regulatory folks whose sole responsibility is to ensure that the company isn’t getting into trouble with regulators. Many of these internal folks are charged specifically with making sure marketing teams aren’t putting the company at risk with a program that violates regulations. As a former pharma marketer, I know these folks have prevented me from getting into what likely would have been some pretty hot water over the years. That’s what they do. However, in some cases, marketers view these internal groups as another obstacle to getting their program into the market. I’m sure that at some companies this is truly the case. I don’t have a lot of advice for you if this is your situation.

For those with more enlightened teams who are willing to work closely together, I’ve got some advice that I think can make it even simpler. I mentioned in my talk at the Business Development Institute that, to borrow a term,  “it takes a village” to get a program approved, particularly if that program is social media based. Never before has a single healthcare marketer conceived, developed, and launched a program on his or her own. There are teams of people that help along the way and some of these people are charged with making sure  that the program isn’t going to get the company in trouble. So, if it does “take a village,” how can you get your village on your side?

Here are what I think are the most important things you can do as a marketer give your program the best chance of approval:

  • Know the “why”
  • Become your own toughest critic
  • Check in along the way
  • Be an educator first
  • Force “Yes, if…” instead of “No, because…”
  • Try something

Know the “why”

The regulatory folks at your company aren’t standing in the way of your program because they don’t like you (probably not anyway). They aren’t saying “no” because it’s much simpler to do so. They have good reasons. Likely, they understand both the internal and external rules much better than you do. As you’re developing your program, invest some time in understanding the regulatory rules that are likely to have an impact on your program. If you do this well, then the approval process should be much simpler and it’s going to allow you to be a better partner, as you’ll be able to really understand where your regulatory colleagues’ concerns.

Become your own toughest critic

Be honest. You know the flaws in the program you’re creating. You know why it will never get approved as is. Why bash your head against the wall then? Be tough on your program just as you know your regulatory team will be. Doing this during the development process is going to force you to rethink things and to look for ways to do them differently. This might be where the big breakthrough comes from. A word of caution: don’t completely stifle an idea because you think it’ll never get approved. That’s an innovation killer. Figure out a different approach that might work or…

Check in along the way

You probably have a very formal process for reviewing a new program. That’s good. But sometimes, you need to go outside this process a bit. As you’re developing your program and run into something that you think is going to give your regulatory team (and therefore federal regulators) heartburn, ask. Ask someone on your regulatory team for advice. You can do this rather informally and it may save you a ton of heartbreak and money later on. It makes no sense to completely develop a program (including all the resources you’ll use) only to find out that the key component is a complete non-starter. Check in before you commit too much to see where the problems might lie. You can not only do this internally, but also externally as well. You can request a meeting with DDMAC (the pharma marketing arm of FDA), for example, to review an idea before it’s complete. They will give you their take on why or why not your program is all right. This is a formal process that your regulatory team can help you set up. If you’re thinking about a really big, really innovative program, don’t get a million dollars into it before you figure out that DDMAC will never allow it. Take advantage of these meetings. Your fees and tax dollars are paying for them anyway.

Be an educator first

You may be a social media expert. Great. Chances are that the people who have to approve your program aren’t. That’s a problem. While you’ve invested a lot of time figuring out how to, say, do a brand page on Facebook that will be compliant, your regulatory teams might not understand the finer points of Facebook. Because of this, they only can go on what they’ve heard or read. We all know that’s not enough. You never really understand the finer points of a channel until you dig in yourself. That’s part of your job. While you can argue that it’s also part of your regulatory team’s job too, it might not be happening that way. That’s where you come in. Educate your team. Teach them about emerging channels and the benefits and risks of each ahead of time. Don’t try to teach them about Twitter in the meeting where you’re asking for approval to do a branded Twitter page. It’s a little late then. (My company, Bridge Worldwide, via WPP, offers a “Digital Immersion” program that can do this sort of training as a one-day seminar. Contact me if you’re interested in hearing more.)

Force “Yes, if…” instead of “No, because…”

This one isn’t mine, but I had to use it because it says it all so perfectly. It comes from Marc Monseau, Director, Media Relations at Johnson & Johnson. You may have heard his name from the J&J blog he helps edit or the J&J Twitter account that he manages. Both, in my opinion, are the standard in healthcare. Marc sent this tweet a couple weeks ago in connection with the Business Development Institute (#BDI) conference I mentioned earlier:

jnjcommtweet1

Think about that for a minute. Which do you hear when you propose something to your regulatory group? The first one, “Yes, if…”, indicates someone who’s willing to help you find a way to make your idea possible. You might not like the concession, but it’s a step forward. The latter, “No, because…”, tells me that this regulatory person isn’t interested in a solution, but rather just in following the company’s and federal regulatory rules. It doesn’t have to be that way though. Force your regulatory teams to think about the issue with “Yes, if…” instead of “No, because…” It’s a powerful difference. You can enable this by talking this way yourself during the discussions with your regulatory team. Come prepared with alternatives and be willing to compromise (assuming it doesn’t kill the intent of your program), but also encourage your colleagues to do the same. PS: you might want to add that this idea comes from J&J, who probably has the most robust social media program of any healthcare company.

Try something

This isn’t “Do something just for the sake of doing it.” Here, I want you to try something because I want you to test all of the above. If your company hasn’t delved into any major social media initiatives and you suddenly spring one on them, expect it to be denied pretty quickly. Instead, do something small now. Maybe an unbranded Facebook page. It doesn’t have to be incredibly robust and the point isn’t to get thousands of people to join. Your goal is to test your process. The process for approving a social media program might be completely different than any other program. Do you know the process? Is there a process? Maybe you need approval from a higher level or the PR/corporate communications team needs a say. The process may be totally different from everything else. Figure it out now, so that when your big program comes up for review, people will be familiar with the process and you won’t have to waste time figuring it out. Also, if you need to respond very quickly to something in the social media space, you can’t waste time creating a process, as things happen in hours, not weeks when it comes to social media.

These six steps are designed to help you and your company advance its social media program. In the end, you’ll need a lot of people to buy into it, so make it as simple as possible. Like many things in life, getting a major program (that also relies on a newer channel) approved involves some selling. These tips hopefully make your sales call just a bit easier.

Greetings from the Business Development Institute Conference

Yesterday, I had the chance to speak at the Business Development Institute’s Social Communications & Healthcare Case Studies and Roundtables Conference. It was a well-done conference with about 350 people in attendance, which is a pretty big number these days. I also got to meet in person some of my Twitter friends, which was great.

Speaking of Twitter, there was quite a bit of participation during the conference and you can run through the entire stream. You can search for #bdi or review it all in real time here.

My talk was called Healthcare & Social Media: Know the Rules. You can listen to my talk using the player below, but first, you can download a PDF version of the presentation so you can follow along (though you’ll have to guess a bit when to flip to the next slide): Healthcare and Social Media...Know the Rules. My talk starts around the 68:08 minute mark if you want to jump to it. For the record, I did not provide this introduction to Steve, the host of the conference. Seriously. [If you're viewing this in an RSS reader or email client, you'll most likely have to click through to the post for the player to work.]

The version you can download above is exactly what I presented in New York. However, you probably noticed that there aren’t many words on the slides (a pet peeve of mine). What this means is that without my “script” these probably don’t make that much sense. So, here’s a PDF of a fully annotated version with more details on the slides, a few slides that I had to cut because of time, and my full speaking notes. Here’s the link: Annotated Version of Healthcare and Social Media...Know the Rules

You also might be interested in the Pharma and Healthcare Social Media Wiki, which I mentioned in my talk. It’s where you can find a bunch of examples of other pharma and healthcare companies have ongoing programs in some social media channel.

A few more things while I’ve got you here…

Don’t forget to subscribe, so you don’t miss anything in the future.

Subscribe to the Dose of Digital RSS Feed

I can also send you an email anytime I publish a new white paper. Interested? Fill in the form below. Rest assured that your email will never be sold, rented, or shared with anyone. I hate spam more than you do. If you’re viewing this in an RSS reader or email client, you’ll have to click through to the post for the form to work.


* indicates required

Lastly, be sure to check out the Mini White Paper Series. These are posts on a general issue that can be re-applied to many other situations. For example, my post on The Myth of Adverse Event Reporting covers how pharma can deal with adverse event reports and how often they really occur online. The information in that post can be used in a number of different situations. So, that’s what it takes to be a “Mini White Paper.” And, yes, they’re long. So, here are all the articles that currently feature the Mini White Paper icon:

Mini White Paper

« Newer PostsOlder Posts »